Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence

Gefitinib, an epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI), has been approved in Japan for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) based on Phase II clinical trials since 2002. Erlotinib, another EGFR-TKI, was also approved a few years thereafter. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Togashi, Yosuke, Hayashi, Hidetoshi, Nakagawa, Kazuhiko, Nishio, Kazuto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124069/
https://www.ncbi.nlm.nih.gov/pubmed/25114510
http://dx.doi.org/10.2147/DDDT.S50358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124069/
https://www.ncbi.nlm.nih.gov/pubmed/25114510
http://dx.doi.org/10.2147/DDDT.S50358

Ejemplares similares